NEW YORK (GenomeWeb News) – DiaTech Oncology has struck a license agreement with Vanderbilt University for a microkinetic assay that can be used to determine a patient's chemotherapy treatment and dosing needs, the university said today.

The Brentwood, Tenn.-based company has licensed the MiCK test, which was developed at the Vanderbilt University School of Medicine, which will be used in a service that measures the response through apoptosis of patients' cancer cells to a number of different chemotherapeutic drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.